FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1971881132> ?p ?o ?g. }

• W1971881132 endingPage "845" @default.
• W1971881132 startingPage "836" @default.
• W1971881132 abstract "Aurora kinase A (AURKA), a serine/threonine kinase, has been shown to regulate the cell cycle checkpoint and maintain genomic integrity. AURKA is overexpressed in various carcinomas. Breast cancer 2, early onset (BRCA2) has an important role in maintaining genomic stability and acts as a tumor suppressor. Our recent study suggested that AURKA regulates genomic instability and tumorigenesis through cell cycle dysregulation and suppression of BRCA2 expression. However, the expression of AURKA, BRCA2 and their clinical significance is unknown in endometrioid ovarian cancer. In this study, we determined AURKA and BRCA2 expression in endometrioid ovarian carcinoma and correlated them with clinicopathologic characteristics and patient survival. Immunohistochemical staining was performed in 51 primary endometrioid ovarian carcinoma tumor samples, using tissue microarray. We then analyzed the associations between AURKA and BRCA2 expression and clinical factors (tumor grade, disease stage, surgical type, clinical response, and relapse) and overall and disease-free survival durations. AURKA and BRCA2 expression were found in 48 and 29% of the samples, respectively. The results of Fisher's exact test suggested that AURKA expression was significantly associated with no family history of ovarian cancer (P=0.03) and that BRCA2 expression was associated with early-stage disease (P=0.03), low ascites incidence (P=0.03), younger age (<60) at diagnosis (P=0.03), and low-grade tumors (P<0.01). The nuclear BRCA2 score was negatively correlated with AURKA score (P=0.019, two-tailed Pearson correlation). A log-rank test demonstrated that AURKA expression was associated with shorter overall (P=0.001) and disease-free (P=0.009) survival durations, and that BRCA2 expression was associated with longer overall (P=0.000) and disease-free (P=0.002) durations. Patients with BRCA2-positive and AURKA-negative tumors had higher overall (P=0.001) and disease-free (P=0.001) survival rates than did patients with AURKA-positive and BRCA2-negative tumors. Our results demonstrate that a negative regulatory loop exists between AURKA and BRCA2 expression in the ovarian endometrioid carcinoma. AURKA expression is an unfavorable prognostic factor in patients with endometrioid ovarian cancer and BRCA2 is favorable, combination of these two markers may better predict the prognosis of patients with endometrioid ovarian carcinoma than individual marker alone." @default.
• W1971881132 created "2016-06-24" @default.
• W1971881132 creator A5006094386 @default.
• W1971881132 creator A5009247766 @default.
• W1971881132 creator A5012852198 @default.
• W1971881132 creator A5031499083 @default.
• W1971881132 creator A5084532204 @default.
• W1971881132 date "2011-06-01" @default.
• W1971881132 modified "2023-10-13" @default.
• W1971881132 title "AURKA and BRCA2 expression highly correlate with prognosis of endometrioid ovarian carcinoma" @default.
• W1971881132 cites W1657157395 @default.
• W1971881132 cites W182179909 @default.
• W1971881132 cites W1890251880 @default.
• W1971881132 cites W1958294525 @default.
• W1971881132 cites W1969264492 @default.
• W1971881132 cites W1971245170 @default.
• W1971881132 cites W1971892398 @default.
• W1971881132 cites W1990317973 @default.
• W1971881132 cites W1992181243 @default.
• W1971881132 cites W2006113261 @default.
• W1971881132 cites W2011065238 @default.
• W1971881132 cites W2015094082 @default.
• W1971881132 cites W2031667278 @default.
• W1971881132 cites W2032014551 @default.
• W1971881132 cites W2035179505 @default.
• W1971881132 cites W2037799994 @default.
• W1971881132 cites W2048572064 @default.
• W1971881132 cites W2060619702 @default.
• W1971881132 cites W2060857971 @default.
• W1971881132 cites W2069910776 @default.
• W1971881132 cites W2070239961 @default.
• W1971881132 cites W2091312754 @default.
• W1971881132 cites W2092513942 @default.
• W1971881132 cites W2103243823 @default.
• W1971881132 cites W2119422823 @default.
• W1971881132 cites W2121169754 @default.
• W1971881132 cites W2135179721 @default.
• W1971881132 cites W2145807414 @default.
• W1971881132 cites W2151131844 @default.
• W1971881132 cites W2168050705 @default.
• W1971881132 cites W2170710435 @default.
• W1971881132 cites W2419653285 @default.
• W1971881132 cites W4232721722 @default.
• W1971881132 cites W4368092894 @default.
• W1971881132 doi "https://doi.org/10.1038/modpathol.2011.44" @default.
• W1971881132 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3152794" @default.
• W1971881132 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21441901" @default.
• W1971881132 hasPublicationYear "2011" @default.
• W1971881132 type Work @default.
• W1971881132 sameAs 1971881132 @default.
• W1971881132 citedByCount "55" @default.
• W1971881132 countsByYear W19718811322012 @default.
• W1971881132 countsByYear W19718811322013 @default.
• W1971881132 countsByYear W19718811322014 @default.
• W1971881132 countsByYear W19718811322015 @default.
• W1971881132 countsByYear W19718811322016 @default.
• W1971881132 countsByYear W19718811322017 @default.
• W1971881132 countsByYear W19718811322018 @default.
• W1971881132 countsByYear W19718811322019 @default.
• W1971881132 countsByYear W19718811322020 @default.
• W1971881132 countsByYear W19718811322021 @default.
• W1971881132 countsByYear W19718811322022 @default.
• W1971881132 crossrefType "journal-article" @default.
• W1971881132 hasAuthorship W1971881132A5006094386 @default.
• W1971881132 hasAuthorship W1971881132A5009247766 @default.
• W1971881132 hasAuthorship W1971881132A5012852198 @default.
• W1971881132 hasAuthorship W1971881132A5031499083 @default.
• W1971881132 hasAuthorship W1971881132A5084532204 @default.
• W1971881132 hasBestOaLocation W19718811321 @default.
• W1971881132 hasConcept C121608353 @default.
• W1971881132 hasConcept C126322002 @default.
• W1971881132 hasConcept C142724271 @default.
• W1971881132 hasConcept C143998085 @default.
• W1971881132 hasConcept C146357865 @default.
• W1971881132 hasConcept C151730666 @default.
• W1971881132 hasConcept C193270364 @default.
• W1971881132 hasConcept C204232928 @default.
• W1971881132 hasConcept C2777546739 @default.
• W1971881132 hasConcept C2780427987 @default.
• W1971881132 hasConcept C2781199814 @default.
• W1971881132 hasConcept C3019054536 @default.
• W1971881132 hasConcept C502942594 @default.
• W1971881132 hasConcept C555283112 @default.
• W1971881132 hasConcept C71924100 @default.
• W1971881132 hasConcept C86803240 @default.
• W1971881132 hasConceptScore W1971881132C121608353 @default.
• W1971881132 hasConceptScore W1971881132C126322002 @default.
• W1971881132 hasConceptScore W1971881132C142724271 @default.
• W1971881132 hasConceptScore W1971881132C143998085 @default.
• W1971881132 hasConceptScore W1971881132C146357865 @default.
• W1971881132 hasConceptScore W1971881132C151730666 @default.
• W1971881132 hasConceptScore W1971881132C193270364 @default.
• W1971881132 hasConceptScore W1971881132C204232928 @default.
• W1971881132 hasConceptScore W1971881132C2777546739 @default.
• W1971881132 hasConceptScore W1971881132C2780427987 @default.
• W1971881132 hasConceptScore W1971881132C2781199814 @default.
• W1971881132 hasConceptScore W1971881132C3019054536 @default.
• W1971881132 hasConceptScore W1971881132C502942594 @default.

• next